CJC-1295 Side Effects Reported in Studies
Phase-1 CJC-1295 trials found several short-term effects. FDA also raised concerns, and long-term safety remains unknown.
Which CJC-1295 side effects did studies report?
Healthy adults reported short-lived CJC-1295 effects in phase-1 safety tests [1][16]. Common ones were shot-site skin trouble, facial flushing, headache, and mild nausea.
No serious event appeared at the tested amounts. One-shot amounts ran from 30 to 250 micrograms based on each kilogram the person weighed.
The longer CJC-1295 test used 60 micrograms per kilogram, with shots weekly or every other week. It was a 49-day trial [16].
FDA reviewed the safety record in a 2024 paper [13]. FDA raised concerns about the heart and immune system.
FDA also warned that small drug pieces may stick together. Such clumps could change how the immune system reacts.
No published study tells you the long-term human risk. That short test leaves a large gap.
Why might CJC-1295 cause flushing?
Facial flushing was common in the 2006 phase-1 trial [1]. It came on soon after CJC-1295 with DAC.
The phase-1 flushing didn't last. Growth-hormone release can briefly widen blood vessels [1].
That widening can make the face feel warm or look red. The tested group needed no care for it.
The trial only covered its tested amounts. It doesn't settle risk at other amounts; it also doesn't tell us long-term risk.
Did CJC-1295 studies find hair loss?
Published phase-1 trials didn't report hair loss [1][16]. But those phase-1 trials weren't built to study hair.
They didn't count or track hair changes. Some people online say they noticed hair loss.
Those are reports from users, not findings from a controlled trial. No trial has checked the claim.
So the papers don't prove that CJC-1295 causes hair loss. Nor can they tell you it cannot; the answer remains unknown.
Did CJC-1295 studies measure weight or fat?
The phase-1 human trials focused on blood tests [1][4][16]. They checked growth hormone, IGF-1, a liver-made hormone, and other blood proteins.
Scale weight wasn't a main result. A 2006 study did measure body changes in mice [3].
Those mice lacked the body's usual hormone message that starts the gland. Daily CJC-1295 restored their weight and tissue apart from fat.
Fat under the skin also returned to control levels. That happened in mice made for this kind of test.
The mouse result doesn't prove the same change in people. This drug group can also cause the body to hold water.
Long-term human CJC-1295 evidence is thin. A doctor can't draw firm CJC-1295 results from it.
Has CJC-1295 been studied for fertility?
No published human trial has tested CJC-1295 and fertility. Public papers also lack animal studies of birth safety for this compound.
The direct answer isn't known. CJC-1295 first affects insulin-like growth factor 1 and growth hormone.
It doesn't act first on hormones tied to sex and fertility. Any effect on fertility might be indirect, but that is only a guess.
A guess isn't study proof. If fertility matters to you, take this gap to your doctor.
What are the biggest CJC-1295 safety gaps?
Phase-1 trials found no serious event at the tested amounts [1][16]. One-time amounts reached 250 micrograms per kilogram.
Another group got 60 micrograms per kilogram for 49 days. CJC-1295 isn't FDA-approved for any use [13].
Short trials can't answer your long-term safety questions. There is no long human follow-up.
A phase-2 trial studied abnormal body-fat loss or gain in people with the same virus. The trial stopped after a fatal heart event [14].
The event came about two hours after the eleventh weekly dose. The trial doctor blamed clogged heart arteries that were already present.
The sponsor also judged the death unrelated to the compound. Still, the work didn't move past phase 2.
In 2023, FDA placed CJC-1295 in Category 2 on the 503A pharmacy list [13]. That list covers drugs pharmacies may ask to make specially for one person.
That group meant major safety worries. FDA cited clumping, immune reactions, and reports of harm.
FDA's safety page, current as of April 22, 2026, puts CJC-1295 in the table of withdrawn nominations and keeps the safety warnings next to it [13]. Its backer withdrew the request; FDA didn't clear the drug as safe.
What other rules and risks matter?
WADA lists CJC-1295 in Section S2.2 [12]. That rule covers drugs that make the body release growth hormone.
Athletes under the WADA Code can't use it at any time. Sellers often call it a 'research chemical,' but FDA doesn't oversee many such sellers.
One lab identified the compound in one seized sample [5]. That doesn't show what any other product contains or how clean it is.
Insulin-like growth factor 1 and long-lasting growth hormone raise questions about blood sugar, cancer, and body changes. Published CJC-1295 work hasn't settled those risks.